$SUPN (Supernus Pharmaceuticals, Inc.)

$SUPN {{ '2016-05-10T13:21:15+0000' | timeago}} • Announcement

$SUPN said it has dismissed two patent infringement actions pending in the U.S. District Court for the District of New Jersey against Actavis and its subsidiaries, pursuant to a confidential partial settlement agreement. The dismissed actions concerned two of Supernus' Orange Book patents covering Oxtellar XR.

$ABT {{ '2017-10-18T13:13:48+0000' | timeago}} • Infographic

$ABT Abbott Laboratories Earnings AlphaGraphic: Q3 2017 Highlights

$UNH {{ '2017-10-17T19:30:35+0000' | timeago}} • Announcement

$UNH is the first firm amongst its peers to report earnings every quarter. For the first time in its history, it is on track to cross revenues of $200Bil in 2017. 3Q revenues jumped 9% to $50.3Bil. $UNH's withdrawal from ACA individual insurance markets, along with a health insurance tax deferral, reduced revenues by $1.6Bil and growth rate by 4%.

$JNJ {{ '2017-10-17T19:25:16+0000' | timeago}} • Webcast

$JNJ said, "The key factor to Remicade being successful is physicians and patients have a high confidence in it based on experience that they don't want to switch to an alternative." The company was responding to a question on rival $PFE's lawsuit against it for allegedly using unfair means to protect Remicade from competitors.

$JNJ {{ '2017-10-17T19:18:23+0000' | timeago}} • Webcast

$JNJ said sale of its blockbuster drug Remicade, used in the treatment of rheumatoid-arthritis declined 7.6% to $1.6Bil in 3Q17, hurt by competition from cheaper alternatives called biosimilars. The pharma giant said it has reduced Remicade's price, in view of tight competition in the market.

$JNJ {{ '2017-10-17T18:41:27+0000' | timeago}} • Webcast

Speaking on the effect of Hurricane Maria that hit Puerto Rico last month, $JNJ said all six of its plants on the island are making and shipping drugs using energy from generators. Though the company said intermittent shortage of drugs cannot be ruled out, it added that it does not see any material impact of the hurricane on future results.

$UNH {{ '2017-10-17T17:16:02+0000' | timeago}} • Announcement

$UNH reported 26% jump in its profits aided by strong growth in its Optum business. This is the first quarter the health insurer is reporting results under the helm of new CEO Dave Wichmann, who replaced Steve Hemsley in September. The company also raised its outlook for 2017. It now expects GAAP EPS to touch $9.45 and adjusted EPS to reach $10.

$MYL {{ '2017-10-17T16:40:23+0000' | timeago}} • Announcement

$MYL announced that the United States District Court for the Eastern District of Texas issued a decision finding all asserted claims of the patents relating to Restasis invalid. The Court recognized that $AGN's patent protection for Restasis ended in 2014.

$AMGN {{ '2017-10-17T14:34:06+0000' | timeago}} • Announcement

$AMGN has entered into a neuroscience research collaboration with Boston Children's Hospital, which aims at identifying novel pain targets based on human genetic analyses. The one-year collaboration will focus on patients with genetic anomalies of pain sensitivity.

$JNJ {{ '2017-10-17T13:40:49+0000' | timeago}} • Webcast

Only months after promising investors a slew of new blockbuster drugs, $JNJ said it has decided to discontinue clinical trials for two of its drugs. Sirukumab, for the treatment of rheumatoid arthritis, and talacotuzumab, for the treatment of myeloid leukemia, are the drugs that have been discontinued.

$JNJ {{ '2017-10-17T12:09:28+0000' | timeago}} • Infographic

$JNJ Johnson & Johnson Earnings AlphaGraphic: Q3 2017 Highlights

$UNH {{ '2017-10-17T11:55:37+0000' | timeago}} • Infographic

$UNH UnitedHealth Earnings AlphaGraphics: Q3 2017 Highlights

$JNJ {{ '2017-10-17T11:47:16+0000' | timeago}} • Announcement

$JNJ raised its sales and adjusted earnings guidance for FY17. The New Brunswick, NJ-based healthcare giant now expects sales for the period to be in the range of $76.1 - 76.5Bil, verses the prior guidance of $75.8 - 76.1Bil. Adjusted earnings is anticipated to be $7.25 - $7.30 per share, compared to the prior guidance of $7.12 - $7.22 per share.

$JNJ {{ '2017-10-17T11:36:50+0000' | timeago}} • Announcement

Kicking off the earnings season in healthcare sector, $JNJ reported 10.3% growth in its sales to $19.7Bil in 3Q17. Adjusted earnings also rose double digits to $5.2Bil, or $1.90 per share, driven by strong growth in Pharma unit, as well as Actelion acquisition. On a GAAP basis, earnings fell 12% to $3.8Bil, or $1.37 per share.

$AGN {{ '2017-10-16T21:26:34+0000' | timeago}} • Announcement

Drugmaker $AGN gets an adverse effect from the U.S. District Court for the Eastern District of Texas. The judge invalidated Allergan's Restasis patent deal, which was signed with the Mohawk Tribe in the last month. Allergan plans to appeal the ruling. Restasis, a dry-eye treatment drug,  generated $1.5Bil of revenues for Allergan in 2016.

$REGN {{ '2017-10-16T14:56:28+0000' | timeago}} • Announcement

$REGN and $SNY announced positive results from a Phase 2 study of dupilumab in adults with active moderateto-severe eosinophilic esophagitis (a condition that causes swallowing difficulty). The study showed that patients who received dupilumab weekly reported a significant improvement in the ability to swallow versus placebo.

$JNJ {{ '2017-10-16T14:43:30+0000' | timeago}} • Announcement

$JNJ said Janssen Biotech Inc. has received FDA approval for an expanded indication for STELARA for the treatment of adolescents with plaque psoriasis.

$REGN {{ '2017-10-16T13:04:52+0000' | timeago}} • Announcement

$REGN and Sanofi announced positive results from a Phase 2 investigational study of dupilumab in adults with active moderate-to-severe eosinophilic esophagitis. Eosinophilic esophagitis is a chronic, allergic inflammatory disease that damages the esophagus and prevents it from working properly, leading to difficulties swallowing and food impaction.

$AGN {{ '2017-10-12T22:44:22+0000' | timeago}} • Announcement

$AGN, which inked a controversial patent deal with Mohawk Tribe, reached a patent litigation settlement on its dry eye treatment drug Restasis with InnoPharma, a unit of $PFE. The litigation, which was filed in Sept. 2015 by Allergan, will be withdrawn and Allergan will grant license to InnoPharma to market Restasis from Feb. 2024 or earlier.

$AGN {{ '2017-10-10T18:02:39+0000' | timeago}} • Announcement

FDA accepts to review $AGN's New Drug Application seeking approval for ulipristal acetate, an investigational drug for the treatment of abnormal bleeding in women with uterine fibroids. Allergan expects the action date to occur in 1H18. According to the Agency for Healthcare Research and Quality (AHRQ), 26MM women in U.S. have got uterine fibroids.

$VRX {{ '2017-10-10T14:50:38+0000' | timeago}} • Infographic

$VRX's progress towards paying down a huge debt of $5Bil before Feb 2018.

Recent Transcripts

UNH (UnitedHealth Group Incorporated)
Tuesday, October 17 2017 - 12:45pm
JNJ (Johnson & Johnson)
Tuesday, October 17 2017 - 12:30pm
MYL (Mylan N.V.)
Wednesday, August 9 2017 - 2:00pm
CCXI (ChemoCentryx, Inc.)
Tuesday, August 8 2017 - 9:00pm
DRRX (DURECT Corporation)
Tuesday, August 8 2017 - 8:30pm
VRX (Valeant Pharmaceuticals International, Inc.)
Tuesday, August 8 2017 - 12:00pm
DEPO (DepoMed Inc.)
Monday, August 7 2017 - 8:30pm
SUPN (Supernus Pharmaceuticals, Inc.)
Thursday, August 3 2017 - 1:00pm
REGN (Regeneron Pharmaceuticals, Inc.)
Thursday, August 3 2017 - 12:30pm
AGN (Allergan plc)
Thursday, August 3 2017 - 12:30pm
TRXC (TransEnterix, Inc.)
Wednesday, August 2 2017 - 8:30pm
PFE (Pfizer Inc.)
Tuesday, August 1 2017 - 2:00pm
ALKS (Alkermes plc)
Thursday, July 27 2017 - 12:30pm
AMGN (Amgen Inc)
Tuesday, July 25 2017 - 9:00pm
ISRG (Intuitive Surgical, Inc.)
Thursday, July 20 2017 - 8:30pm
ABT (Abbott Laboratories)
Thursday, July 20 2017 - 1:00pm
UNH (UnitedHealth Group Incorporated)
Tuesday, July 18 2017 - 12:45pm
JNJ (Johnson & Johnson)
Tuesday, July 18 2017 - 12:30pm
CCXI (ChemoCentryx, Inc.)
Wednesday, May 10 2017 - 9:00pm
DRRX (DURECT Corporation)
Wednesday, May 10 2017 - 8:30pm

AlphaGraphics you may like